Effects of the novel non-steroidal anti-inflammatory compound [N-(2-thiolethyl)-2- {2- [N'- (2,6- dichlorophenyl) amino] phenyl}acetamide on cytokines and apoptosis in ischaemic rat brain. 2006

Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
Department of Genetics, Development and Molecular Biology, School of Biology, Faculty of Sciences, Aristotelian University of Thessaloniki, Thessaloniki, Greece.

Ischaemia-reperfusion injury is associated with an inflammatory response as well as apoptosis in the affected area. Inflammatory responses are characterized, among others, by an increased production of several cytokines, while caspases are implicated in the control of apoptosis. The aim of the present work was to determine changes in the levels of inflammatory and apoptotic indices in the rat brain after cerebral ischaemia-reperfusion and to evaluate the effect of the non-steroidal anti-inflammatory compound N-(2-thiolethyl)-2-{2-[N'-[2,6-dichlorophenyl)aminolphenyl} acetamide on these indices. A cerebral ischaemia-reperfusion rodent model was used to investigate, via immunohistochemical and colorimetric techniques, the presence in the brain and spleen of inflammatory enzymes cycloxygenases COX-1 and COX-2, cytokines interleukin (IL)-1beta, IL-4, IL-6, IL-10, IL-18, tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) as well as the activated form of caspase-3, in treated and untreated animals. Cerebral ischaemia-reperfusion caused elevated levels in the rat post ischaemia. Treatment with the antiinflammatory derivative reduced the elevation, caused by ischaemia, of IFN-gamma, TNF-alpha, IL-1beta IL-6, IL-18 and caspase-3 levels at 3 days post ischaemia, while it increased the levels of IL-10. It was shown that the increase in concentrations of a wide range of cytokines involved in the inflammatory reaction causing brain damage after ischaemia-reperfusion can be partially reversed by the anti-inflammatory derivative used in this study.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D003124 Colorimetry Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.

Related Publications

Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
April 1973, Experientia,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
October 2001, Acta crystallographica. Section C, Crystal structure communications,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
March 1973, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
June 2016, Life sciences,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
January 2010, Acta poloniae pharmaceutica,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
June 1987, Archiv der Pharmazie,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
October 1975, Arzneimittel-Forschung,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
May 2018, BMC musculoskeletal disorders,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
March 1973, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Nikos Peroulis, and Angeliki P Kourounakis, and Minas Yiangou, and Daniel Paramythiotis, and Katerina Kotzampassi, and Lygeri Hadjipetrou
January 1998, Acta poloniae pharmaceutica,
Copied contents to your clipboard!